PURPOSE: A novel, (18)F-labelled metabotropic glutamate receptor subtype 5 (mGlu5) derivative of [(11)C]ABP688 ([(11)C]1), [(18)F]PSS232 ([(18)F] ]5), was evaluated in vitro and in vivo for its potential as a PET agent and was used in test-retest reliability studies METHODS: The radiosynthesis of [(18)F]5 was accomplished via a one-step reaction using a mesylate precursor. In vitro stability was determined in PBS and plasma, and with liver microsomal enzymes. Metabolite studies were performed using rat brain extracts, blood and urine. In vitro autoradiography was performed on horizontal slices of rat brain using 1 and 8, antagonists for mGlu5 and mGlu1, respectively. Small-animal PET, biodistribution, and test-retest studies were performed in Wistar rats. In vivo, dose-dependent displacement studies were performed using 6 and blocking studies with 7. RESULTS: [(18)F]5 was obtained in decay-corrected maximal radiochemical yield of 37 % with a specific activity of 80 - 400 GBq/μmol. Treatment with rat and human microsomal enzymes in vitro for 60 min resulted in 20 % and 4 % of hydrophilic radiometabolites, respectively. No hydrophilic decomposition products or radiometabolites were found in PBS or plasma. In vitro autoradiography on rat brain slices showed a heterogeneous distribution consistent with the known distribution of mGlu5 with high binding to hippocampal and cortical regions, and negligible radioactivity in the cerebellum. Similar distribution of radioactivity was found in PET images. Under displacement conditions with 6, reduced [(18)F]5 binding was found in all brain regions except the cerebellum. 7 reduced binding in the striatum by 84 % on average. Test-retest studies were reproducible with a variability ranging from 6.8 % to 8.2 %. An extended single-dose toxicity study in Wistar rats showed no compound-related adverse effects. CONCLUSION: The new mGlu5 radiotracer, [(18)F]5, showed specific and selective in vitro and in vivo properties and is a promising radioligand for PET imaging of mGlu5 in humans.
PURPOSE: A novel, (18)F-labelled metabotropic glutamate receptor subtype 5 (mGlu5) derivative of [(11)C]ABP688 ([(11)C]1), [(18)F]PSS232 ([(18)F] ]5), was evaluated in vitro and in vivo for its potential as a PET agent and was used in test-retest reliability studies METHODS: The radiosynthesis of [(18)F]5 was accomplished via a one-step reaction using a mesylate precursor. In vitro stability was determined in PBS and plasma, and with liver microsomal enzymes. Metabolite studies were performed using rat brain extracts, blood and urine. In vitro autoradiography was performed on horizontal slices of rat brain using 1 and 8, antagonists for mGlu5 and mGlu1, respectively. Small-animal PET, biodistribution, and test-retest studies were performed in Wistar rats. In vivo, dose-dependent displacement studies were performed using 6 and blocking studies with 7. RESULTS: [(18)F]5 was obtained in decay-corrected maximal radiochemical yield of 37 % with a specific activity of 80 - 400 GBq/μmol. Treatment with rat and human microsomal enzymes in vitro for 60 min resulted in 20 % and 4 % of hydrophilic radiometabolites, respectively. No hydrophilic decomposition products or radiometabolites were found in PBS or plasma. In vitro autoradiography on rat brain slices showed a heterogeneous distribution consistent with the known distribution of mGlu5 with high binding to hippocampal and cortical regions, and negligible radioactivity in the cerebellum. Similar distribution of radioactivity was found in PET images. Under displacement conditions with 6, reduced [(18)F]5 binding was found in all brain regions except the cerebellum. 7 reduced binding in the striatum by 84 % on average. Test-retest studies were reproducible with a variability ranging from 6.8 % to 8.2 %. An extended single-dose toxicity study in Wistar rats showed no compound-related adverse effects. CONCLUSION: The new mGlu5 radiotracer, [(18)F]5, showed specific and selective in vitro and in vivo properties and is a promising radioligand for PET imaging of mGlu5 in humans.
Authors: C Chiamulera; M P Epping-Jordan; A Zocchi; C Marcon; C Cottiny; S Tacconi; M Corsi; F Orzi; F Conquet Journal: Nat Neurosci Date: 2001-09 Impact factor: 24.884
Authors: H Umesha Shetty; Sami S Zoghbi; Fabrice G Siméon; Jeih-San Liow; Amira K Brown; Pavitra Kannan; Robert B Innis; Victor W Pike Journal: J Pharmacol Exp Ther Date: 2008-09-19 Impact factor: 4.030
Authors: F Gasparini; K Lingenhöhl; N Stoehr; P J Flor; M Heinrich; I Vranesic; M Biollaz; H Allgeier; R Heckendorn; S Urwyler; M A Varney; E C Johnson; S D Hess; S P Rao; A I Sacaan; E M Santori; G Veliçelebi; R Kuhn Journal: Neuropharmacology Date: 1999-10 Impact factor: 5.250
Authors: Selena Milicevic Sephton; Linjing Mu; W Bernd Schweizer; Roger Schibli; Stefanie D Krämer; Simon M Ametamey Journal: J Med Chem Date: 2012-08-09 Impact factor: 7.446
Authors: Cindy A Baumann; Linjing Mu; Nicole Wertli; Stefanie D Krämer; Michael Honer; Pius A Schubiger; Simon M Ametamey Journal: Bioorg Med Chem Date: 2010-06-25 Impact factor: 3.641
Authors: A Pilc; A Kłodzińska; P Brański; G Nowak; A Pałucha; B Szewczyk; E Tatarczyńska; E Chojnacka-Wójcik; J M Wierońska Journal: Neuropharmacology Date: 2002-08 Impact factor: 5.250
Authors: Selena Milicevic Sephton; Patrick Dennler; Dominique S Leutwiler; Linjing Mu; Cindy A Wanger-Baumann; Roger Schibli; Stefanie D Krämer; Simon M Ametamey Journal: Am J Nucl Med Mol Imaging Date: 2011-12-10
Authors: Kristina Herfert; Julia G Mannheim; Laura Kuebler; Sabina Marciano; Mario Amend; Christoph Parl; Hanna Napieczynska; Florian M Maier; Salvador Castaneda Vega; Bernd J Pichler Journal: Mol Imaging Biol Date: 2020-04 Impact factor: 3.488
Authors: Adrienne Müller Herde; Yoan Mihov; Stefanie D Krämer; Linjing Mu; Antoine Adamantidis; Simon M Ametamey; Gregor Hasler Journal: Neurotox Res Date: 2019-05-22 Impact factor: 3.911
Authors: Adrienne Müller Herde; Roger Schibli; Markus Weber; Simon M Ametamey Journal: Eur J Nucl Med Mol Imaging Date: 2018-10-05 Impact factor: 9.236
Authors: Susanne Weigend; Sebastian C Holst; Valérie Treyer; Ruth L O'Gorman Tuura; Josefine Meier; Simon M Ametamey; Alfred Buck; Hans-Peter Landolt Journal: Sleep Date: 2019-10-21 Impact factor: 5.849